2.5. Statistical Analysis
Data from this study were analyzed in safety, full analysis (FA), and per protocol (PP) sets. The safety set included all patients who received at least one drug during the study. The FA set included all patients for whom primary efficacy endpoints were obtained at least once before the end of the study. The PP set comprised patients who completed the clinical trial without violating the study protocol. Efficacy evaluation data were obtained from the FA and PP sets. Safety evaluation data were obtained from the safety set.All statistical analyses were performed using SPSS (version 27.0; IBM Corp., Armonk, NY, USA). Continuous variables were expressed as mean and standard deviation, while categorical variables were expressed as number and percentage. A two-sided test with a significance level of 5% was used for all analyses. A repeated-measures analysis of variance (ANOVA) was conducted to analyze the primary efficacy endpoint. The within-subject factor was time, with three levels. The independent sample 